{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:02:35Z","timestamp":1782633755573,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Blueprint Medicines"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) (\u00a9Blueprint Medicines Corporation), a 12-item daily diary that assesses 11 signs and symptoms of indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis (SSM), was psychometrically evaluated among patients with ISM. Additionally, thresholds of the ISM-SAF total symptom score (TSS) to distinguish patients with moderate to severe symptoms from those with mild symptoms were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The ISM-SAF was completed daily as an electronic diary in a prospective, observational study utilizing an online survey of patients with ISM in the United States. Descriptive statistics, psychometric analyses, and analyses to estimate ISM-SAF TSS clinical cutoff values were conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 103 patients (81.6% female; mean age\u2009=\u200950.2 [\u00b1\u200912.6]) with a self-reported diagnosis of ISM or SSM (58 of whom also had a medically documented diagnosis) contributed to the analyses. Psychometric analysis supported the trustworthiness of the biweekly TSS, which was reliable (<jats:italic>\u03b1<\/jats:italic>\u2009&gt;\u20090.8, ICC\u2009&gt;\u20090.9), construct-valid, and able to distinguish among clinically distinct groups as specified by the Patient Global Impression of Severity, 12-item Short-Form Health Survey, and Mastocytosis Quality of Life Questionnaire (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). A biweekly ISM-SAF TSS from 21 to 28 begins to distinguish the moderately to severely symptomatic ISM\/SSM patients from mildly symptomatic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The biweekly TSS of ISM-SAF was reliable, construct-valid, and able to distinguish among clinically distinct groups. A cut-off value of 28 is a conservative threshold that can be used for screening purposes in future clinical studies to identify patients with at least a moderate severity of ISM symptoms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02661-1","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T03:02:59Z","timestamp":1679713379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF\u00a9) and determination of a threshold score for moderate symptoms"],"prefix":"10.1186","volume":"18","author":[{"given":"Alan L.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6474-4314","authenticated-orcid":false,"given":"Fiona","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E.","family":"Lamoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kas","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Boral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,25]]},"reference":[{"issue":"8","key":"2661_CR1","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","volume":"28","author":"M Jara-Acevedo","year":"2015","unstructured":"Jara-Acevedo M, Teodosio C, Sanchez-Mu\u00f1oz L, \u00c1lvarez-Twose I, Mayado A, Caldas C, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol. 2015;28(8):1138\u201349.","journal-title":"Mod Pathol"},{"issue":"4","key":"2661_CR2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","volume":"112","author":"DD Metcalfe","year":"2008","unstructured":"Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112(4):946\u201356.","journal-title":"Blood"},{"issue":"4","key":"2661_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bjh.12916","volume":"166","author":"SS Cohen","year":"2014","unstructured":"Cohen SS, Skovbo S, Vestergaard H, Kristensen T, M\u00f8ller M, Bindslev-Jensen C, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166(4):521\u20138.","journal-title":"Br J Haematol"},{"issue":"5","key":"2661_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","volume":"131","author":"JJ van Doormaal","year":"2013","unstructured":"van Doormaal JJ, Arends S, Brunekreeft KL, van der Wal VB, Sietsma J, van Voorst Vader PC, et al. Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol. 2013;131(5):1429-31.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"2661_CR5","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","volume":"113","author":"KH Lim","year":"2009","unstructured":"Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727\u201336.","journal-title":"Blood"},{"issue":"5","key":"2661_CR6","doi-asserted-by":"publisher","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","volume":"3","author":"O Hermine","year":"2008","unstructured":"Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, et al. Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis. PLoSOne. 2008;3(5):e2266.","journal-title":"PLoSOne"},{"issue":"1","key":"2661_CR7","first-page":"70","volume":"2","author":"S Jennings","year":"2014","unstructured":"Jennings S, Russell N, Jennings B, Slee V, Sterling L, Castells M, et al. The mastocytosis society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin ImmunolPract. 2014;2(1):70\u20136.","journal-title":"J Allergy Clin ImmunolPract"},{"issue":"11","key":"2661_CR8","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420\u20137.","journal-title":"Blood"},{"key":"2661_CR9","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: Office of Communications, Division of Drug Information, 2009."},{"issue":"8","key":"2661_CR10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"8","key":"2661_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","volume":"12","author":"M Rothman","year":"2009","unstructured":"Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health. 2009;12(8):1075\u201383.","journal-title":"Value Health"},{"key":"2661_CR12","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients \u2013 Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Draft Guidance. Silver Spring, MD: Office of Communications, Division of Drug Information, 10\/2019."},{"issue":"8","key":"2661_CR13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"key":"2661_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02035-5","author":"F Taylor","year":"2021","unstructured":"Taylor F, Akin C, Lamoureux RE, Padilla B, Green T, Boral AL, Mazar I, Mar B, Shields AL, Siebenhaar F. Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF\u00a9. Orphanet J Rare Dis. 2021. https:\/\/doi.org\/10.1186\/s13023-021-02035-5.","journal-title":"Orphanet J Rare Dis"},{"key":"2661_CR15","unstructured":"SurveyMonkey. HIPAA compliance & surveymonkey 2017 [12\/21\/2017]. Available from: https:\/\/help.surveymonkey.com\/articles\/en_US\/kb\/HIPAA?bc=Legal_Compliance."},{"key":"2661_CR16","unstructured":"US Department of Health and Human Services, Office for Human Research Protections, US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Good Clinical Practice, Center for Biologics Evaluation and Research, et al. Use of electronic informed consent: questions and answers: guidance for institutional review boards, investigators, and sponsors. 2016."},{"key":"2661_CR17","unstructured":"Mitchel JT, Helfgott J. The electronic informed consent has arrived: UBM; 02\/06\/2017 [01\/10\/2018]. Available from: http:\/\/www.appliedclinicaltrialsonline.com\/electronic-informed-consent-has-arrived."},{"key":"2661_CR18","volume-title":"User's manual for the SF-36v2\u00ae","year":"2011","unstructured":"Maruish ME, editor. User\u2019s manual for the SF-36v2\u00ae. 3rd ed. Lincoln: QualityMetric Inc; 2011.","edition":"3"},{"issue":"3","key":"2661_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"JE Ware Jr","year":"1996","unstructured":"Ware JE Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220\u201333.","journal-title":"Med Care"},{"issue":"6","key":"2661_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/all.12842","volume":"71","author":"F Siebenhaar","year":"2016","unstructured":"Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, et al. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy. 2016;71(6):869\u201377.","journal-title":"Allergy"},{"key":"2661_CR21","first-page":"248","volume-title":"Psychometric theory","author":"JC Nunnally","year":"1994","unstructured":"Nunnally JC. The assessment of reliability. In: Bernstein I, editor. Psychometric theory. New York: McGraw Hill; 1994. p. 248\u201392."},{"issue":"2","key":"2661_CR22","first-page":"420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. PsycholBull. 1979;86(2):420\u20138.","journal-title":"PsycholBull"},{"key":"2661_CR23","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Lawrence Earlbaum Associates; 1988."},{"issue":"1","key":"2661_CR24","first-page":"155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. PsycholBull. 1992;112(1):155\u20139.","journal-title":"PsycholBull"},{"issue":"4","key":"2661_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","volume":"6","author":"DV Cicchetti","year":"1994","unstructured":"Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6(4):284\u201390.","journal-title":"Psychol Assess"},{"key":"2661_CR26","volume-title":"Handbook of psychological assessment","author":"G Groth-Marnat","year":"2009","unstructured":"Groth-Marnat G. Handbook of psychological assessment. 5th ed. Hoboken: Wiley; 2009.","edition":"5"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02661-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02661-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T03:07:58Z","timestamp":1679713678000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02661-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,25]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2661"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02661-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,25]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants were recruited through an advocacy group with study materials approved by a centralized IRB, Schulman IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ALS, FT, REL, BP, and KS are employees of Adelphi Values, which conducted research on behalf of Blueprint Medicines. TG, ALB, and BM are employees of Blueprint Medicines and own stock in the company. CA received research funding and consultancy fees from Blueprint Medicines. FS is or recently was a speaker and\/or advisor for and\/or has received research funding from Allakos, Blueprint, Celldex, Genentech, Moxie, Novartis, and Uriach.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}